Similarly, the relative proximity of daunorubicin, an anthracycline aminoglycoside inhibiting the DNA topoisomerase II (TOP2A and TOP2B), to AML is zc=−1.6, offering network-based support for daunorubicin's therapeutic effect in AML. This evidence concerns the gene TOP2B and acute myeloid leukemia.